Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance

Abstract

Impaired glucose tolerance (IGT) is an increasingly frequent complication of cystic fibrosis (CF). In CF patients, a fast postprandial rise in plasma glucose is typically followed by a delayed but prolonged insulin response. Patients may develop symptoms of both hyper- and hypoglycaemia. The α-glucosidase inhibitor, acarbose, delays the hydrolysis and… (More)
DOI: 10.1007/s004310051119

4 Figures and Tables

Topics

  • Presentations referencing similar topics